The association between cholesterol and mortality in heart failure. Comparison between patients with and without

Tomohiko Sakatani1, Takeshi Shirayama, Yoko Suzaki

  • 1Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

International Heart Journal
|September 15, 2005
PubMed

Insights

Low serum cholesterol indicates a better prognosis for patients with coronary artery disease (CAD) and congestive heart failure (CHF). Conversely, low cholesterol predicts a worse outcome for patients without CAD but with CHF.

Area of Science:

  • Cardiology
  • Clinical Lipidology

Background:

  • Hypercholesterolemia is a known risk factor for coronary artery disease (CAD).
  • However, low serum cholesterol levels have been paradoxically associated with a worse prognosis in patients with congestive heart failure (CHF).

Purpose of the Study:

  • To investigate the prognostic value of serum cholesterol levels in patients diagnosed with congestive heart failure (CHF).

Main Methods:

  • The study included 133 patients hospitalized for progressive heart failure.
  • Lipid profiles were assessed post-discharge, and patients were followed for an average of 2.3 years.
  • Outcomes were analyzed in relation to baseline characteristics and lipid levels, including total cholesterol (TC), HDL, and LDL.

Main Results:

  • Overall mortality was 15.8% (21 deaths) during the follow-up period.
  • Survivors had significantly higher HDL levels compared to non-survivors (P=0.01).
  • In patients with CAD, higher TC was associated with worse outcomes (P=0.004), while in patients without CAD, higher TC predicted better outcomes (P=0.02).

Conclusions:

  • Serum cholesterol has a differential prognostic value in patients with congestive heart failure (CHF) depending on the presence or absence of coronary artery disease (CAD).
  • Low serum total cholesterol (TC) is associated with an improved outcome in CHF patients with CAD.
  • Conversely, low TC predicts a worse outcome in CHF patients without CAD.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...